AU7622000A - Compounds for the treatment of viral-mediated diseases - Google Patents

Compounds for the treatment of viral-mediated diseases

Info

Publication number
AU7622000A
AU7622000A AU76220/00A AU7622000A AU7622000A AU 7622000 A AU7622000 A AU 7622000A AU 76220/00 A AU76220/00 A AU 76220/00A AU 7622000 A AU7622000 A AU 7622000A AU 7622000 A AU7622000 A AU 7622000A
Authority
AU
Australia
Prior art keywords
viral
compounds
treatment
mediated diseases
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76220/00A
Inventor
John Stanford Driscoll
Sim Mui Mui
Yin Hwee Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Molecular and Cell Biology
Original Assignee
Institute of Molecular and Cell Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Molecular and Cell Biology filed Critical Institute of Molecular and Cell Biology
Publication of AU7622000A publication Critical patent/AU7622000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU76220/00A 1999-10-01 2000-09-29 Compounds for the treatment of viral-mediated diseases Abandoned AU7622000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15701799P 1999-10-01 1999-10-01
US60157017 1999-10-01
PCT/US2000/026797 WO2001024785A2 (en) 1999-10-01 2000-09-29 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases

Publications (1)

Publication Number Publication Date
AU7622000A true AU7622000A (en) 2001-05-10

Family

ID=22562034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76220/00A Abandoned AU7622000A (en) 1999-10-01 2000-09-29 Compounds for the treatment of viral-mediated diseases

Country Status (5)

Country Link
EP (1) EP1237546A2 (en)
JP (1) JP2003510352A (en)
AR (1) AR025929A1 (en)
AU (1) AU7622000A (en)
WO (1) WO2001024785A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
BR0317687A (en) 2002-12-23 2005-11-22 4Sc Ag Aromatic compounds as antiinflammatory, immunomodulatory and antiproliferative agents
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056746A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
CL2004000985A1 (en) * 2003-05-16 2005-01-14 Wyeth Corp COMPOUNDS DERIVED FROM PHENYLQUINOLINS; PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS; AND USE TO TREAT OSTEOPOROSIS, PAGET DISEASE, VASCULAR DANO, OSTEOARTRITIS, OSEO CANCER, OVARIC CANCER, PROSTATIC CANCER, HYPERCHOLESTEROLEMIA, ATEROSC
TW200509961A (en) * 2003-05-23 2005-03-16 Pestka Biomedical Lab Inc Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
JP2008512458A (en) 2004-09-07 2008-04-24 ワイス 6H- [1] benzopyrano [4,3-b] quinolines and their use as estrogenic substances
US20100068147A1 (en) * 2006-10-05 2010-03-18 Agency for Science , Technology and Research Dengue diagnosis and treatment
WO2009016812A1 (en) * 2007-07-27 2009-02-05 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia comprising 2-phenylquinoline-4-carboxylic acid derivative as active ingredient
TWI530286B (en) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 Anti-inflammatory agents as virostatic compounds
US8710079B2 (en) 2010-04-23 2014-04-29 National Health Research Institutes Quinoline compounds and their use for treating viral infection
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center Methods for treatment of melanoma
EP2948450A4 (en) * 2013-01-28 2016-11-09 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
AU2018223982B2 (en) * 2017-02-24 2022-02-03 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
JP7373170B2 (en) * 2018-06-22 2023-11-02 オハイオ ステート イノベーション ファウンデーション Methods and compositions for inhibiting dihydroorotate dehydrogenase
CN109864989B (en) * 2019-03-08 2021-07-23 中国农业科学院兰州兽医研究所 Application of brequinar in preparation of drugs for preventing foot-and-mouth disease virus infection
EP3978076A4 (en) * 2019-06-03 2023-02-22 Irimajiri Therapeutics Inc. Cyclic amide compounds for rabies treatment and method thereof
IT202000027251A1 (en) * 2020-11-13 2022-05-13 Donatella Boschi HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITOR FOR USE AS ANTIVIRALS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
WO1993022286A1 (en) * 1992-04-24 1993-11-11 Kyowa Hakko Kogyo Co., Ltd. Novel tetracyclic compound
ES2177583T3 (en) * 1993-09-28 2002-12-16 Kyowa Hakko Kogyo Kk NEW TETRACICLIC COMPOUND.
JPH10231289A (en) * 1996-12-06 1998-09-02 Kyowa Hakko Kogyo Co Ltd Tetracyclic quinoline derivative

Also Published As

Publication number Publication date
WO2001024785A2 (en) 2001-04-12
WO2001024785A3 (en) 2002-07-11
EP1237546A2 (en) 2002-09-11
JP2003510352A (en) 2003-03-18
AR025929A1 (en) 2002-12-18

Similar Documents

Publication Publication Date Title
AU2935200A (en) Compounds for the treatment of obesity
AU2001282873A1 (en) Quinuclidine-substituted aryl compounds for treatment of disease
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU2001284645A1 (en) Quinuclidine-substituted aryl compounds for treatment of disease
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU6910600A (en) Methods for the treatment of mental disorders
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU5038299A (en) Process for the biocidal treatment of surfaces
AU4364400A (en) Azaindole derivatives for the treatment of depression
AU2021601A (en) Composition for the treatment of dandruff
AU5831500A (en) Process for the preparation of polyols
AU1878201A (en) Composition for the treatment of damaged tissue
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
AU3501100A (en) Synergistic combination for treatment of viral-mediated diseases
AU2829700A (en) Processes for the preparation of alpha-aminoketones
AU1940800A (en) Combination therapy for the treatment of sepsis
AU1405001A (en) Treatment of diseases
AU2683500A (en) Compositions for the treatment of pain
AU2000263936A1 (en) Substance p analogs for the treatment of cancer
AU5416500A (en) Pharmaceutical composition for the treatment of calcification
AU7534800A (en) Processes for the preparation of chemical compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase